'I have three kids that need a mom': Defiance family facing cancer fight with compassion

Defiance firefighter Chad Brown's wife, Amber, was diagnosed with stage three squamous cell carcinoma in January 2025.

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Detailed price information for Pyxis Oncology Inc (PYXS-Q) from The Globe and Mail including charting and trades.

How $594B in Precision Tech is Cracking the Metastatic Cancer Code

The global cancer drugs market is surging toward $594.3 billion by 2035 as high-tech immunotherapies begin to replace ...

Purple Biotech Achieves Toxicology Milestone Demonstrating an Expanded Therapeutic Window for CAPTN-3 Platform Tri-specific Antibody, IM1240

IM1240 demonstrated improved safety in a toxicology study at doses up to 300-fold higher than a non-capped comparatorIM1240's ...

Pulitzer-winning photographer with York County roots battles cancer

David Swanson started his photography career as a high schooler covering spot news for The York Dispatch and the York Daily ...
The Manila Times

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic D…

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with ...

Theriva Biologics, Inc.: Theriva Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in ...

EMA provided overall agreement with the proposed Phase 3 clinical trial of VCN-01 in combination with gemcitabine/nab-paclitaxel for the first-line treatment of metastatic PDAC, including sample size ...

Werewolf Therapeutics Announces Pipeline and Business Updates

Detailed price information for Werewolf Therapeutics Inc (HOWL-Q) from The Globe and Mail including charting and trades.
MyHorryNews

Privo Technologies Begins Dosing PRV131 in Arm 3 Of Clinical Study CLN-004, A First-In-Class Cisplatin Intratumoral Injectable Targeting Oral Cavity Cancer

BOSTON, Mass., Dec. 10, 2025 /PRNewswire/ -- Privo Technologies, Inc., today announced that the first patient has been dosed in its first-in-human clinical trial evaluating PRV131, a nanoengineered ...